Mersana Therapeutics announced two executive appointments. Donald A. Bergstrom, M.D., Ph.D., has been appointed Chief Medical Officer, adding substantial experience in oncology translational research to Mersana's team. Eva M. Jack has been appointed Mersana's Chief Business Officer, bringing a successful track record in business development and venture capital.

Dr. Bergstrom joins Mersana after serving since May 2010 as Global Head of Translational and Experimental Medicine at Sanofi Oncology. Ms. Jack joins Mersana after serving as an independent advisor and consultant to biotech companies and investors on business and financing strategies since 2012.